Research on Ginkgolide B increases Cisplatin sensitivity in ovarian cancer cell via down-regulation of excision repair cross-complementing 1(ERCC1) in vitro

Objective: To investigate the effects and mechanisms of ginkgolide B(GB),extract of Ginkgo biloba,on increasing the sensitivity of cisplatin-resistant ovarian cancer cell line(SKOV3/DDP-luc).Methods: SKOV3/DDP-luc cells were pretreated with 25μmol/L of GB for 3,7,and 14 days.Then,cells were exposed to different concentrations of CDDP and incubated for 72 hours.MTT assay was performed to determine the viability of the cells and the IC50 of CDDP was calculated according to the viability curve.Meanwhile,proteins were extracted from the cells treated by GB at different time point and the expression of ERCC1 was detected by Western Blot.Results: After cells were pretreated with GB for 3,7 and 14 days,IC50 of CDDP was significantly decreased to 24.2(P=0.07),18.2(P=0.001) and 11.6μmol/L(P=0.0004),respectively.The expression of ERCC1 protein in every group was decreased accordingly(P0.01).Conclusion: GB can increase the drug sensitivity of CDDP-resistant human ovarian cancer cells significantly,which was implemented through down regulation of the expression of ERCC1.Our results suggested that GB could be a potential supplementary drug in ovarian cancer therapy.